Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

A Novel Anti-Inflammatory Effect for High Density Lipoprotein.

Cameron SJ, Morrell CN, Bao C, Swaim AF, Rodriguez A, Lowenstein CJ.

PLoS One. 2015 Dec 17;10(12):e0144372. doi: 10.1371/journal.pone.0144372. eCollection 2015.

2.

HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis.

Reina SA, Llabre MM, Allison MA, Wilkins JT, Mendez AJ, Arnan MK, Schneiderman N, Sacco RL, Carnethon M, Delaney JA.

Atherosclerosis. 2015 Nov;243(1):314-9. doi: 10.1016/j.atherosclerosis.2015.09.031. Epub 2015 Sep 28.

PMID:
26425994
3.

Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening.

Lin SH, Huang KJ, Weng CF, Shiuan D.

Drug Des Devel Ther. 2015 Jun 26;9:3313-24. doi: 10.2147/DDDT.S84641. eCollection 2015.

4.

Arsenic-induced dyslipidemia in male albino rats: comparison between trivalent and pentavalent inorganic arsenic in drinking water.

Afolabi OK, Wusu AD, Ogunrinola OO, Abam EO, Babayemi DO, Dosumu OA, Onunkwor OB, Balogun EA, Odukoya OO, Ademuyiwa O.

BMC Pharmacol Toxicol. 2015 Jun 5;16:15. doi: 10.1186/s40360-015-0015-z.

5.

Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families.

Kulkarni H, Meikle PJ, Mamtani M, Weir JM, Almeida M, Diego V, Peralta JM, Barlow CK, Bellis C, Dyer TD, Almasy L, Mahaney MC, Comuzzie AG, Göring HH, Curran JE, Blangero J.

J Lipid Res. 2014 May;55(5):939-46. doi: 10.1194/jlr.M044065. Epub 2014 Mar 13.

6.

Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.

Roe A, Hillman J, Butts S, Smith M, Rader D, Playford M, Mehta NN, Dokras A.

J Clin Endocrinol Metab. 2014 May;99(5):E841-7. doi: 10.1210/jc.2013-3918. Epub 2014 Feb 10.

7.

Interaction between VLDL and phosphatidylcholine liposomes generates new γ-LpE-like particles.

Ćwiklińska A, Kortas-Stempak B, Gliwińska A, Pacanis A, Kuchta A, Wróblewska M.

Lipids. 2014 Feb;49(2):143-53.

8.

Genetics of lipid traits and relationship to coronary artery disease.

Keenan TE, Rader DJ.

Curr Cardiol Rep. 2013 Sep;15(9):396. doi: 10.1007/s11886-013-0396-9. Review.

9.

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.

Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL.

Nat Med. 2013 May;19(5):576-85. doi: 10.1038/nm.3145. Epub 2013 Apr 7.

10.

Novel biological functions of high-density lipoprotein cholesterol.

Mineo C, Shaul PW.

Circ Res. 2012 Sep 28;111(8):1079-90. Review.

11.

Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.

Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST.

Ann Rheum Dis. 2012 Jul;71(7):1157-62. doi: 10.1136/annrheumdis-2011-200493. Epub 2012 Jan 20.

12.

Biliary and nonbiliary contributions to reverse cholesterol transport.

Temel RE, Brown JM.

Curr Opin Lipidol. 2012 Apr;23(2):85-90. doi: 10.1097/MOL.0b013e3283508c21. Review.

13.

Insights into the molecular mechanisms of the anti-atherogenic actions of flavonoids in normal and obese mice.

Shabrova EV, Tarnopolsky O, Singh AP, Plutzky J, Vorsa N, Quadro L.

PLoS One. 2011;6(10):e24634. doi: 10.1371/journal.pone.0024634. Epub 2011 Oct 10.

14.

Adipose modulation of high-density lipoprotein cholesterol: implications for obesity, high-density lipoprotein metabolism, and cardiovascular disease.

McGillicuddy FC, Reilly MP, Rader DJ.

Circulation. 2011 Oct 11;124(15):1602-5. doi: 10.1161/CIRCULATIONAHA.111.058453. No abstract available.

15.

A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic women.

Parra ES, Urban A, Panzoldo NB, Nakamura RT, Oliveira R, de Faria EC.

Lipids Health Dis. 2011 May 24;10:87. doi: 10.1186/1476-511X-10-87.

16.

Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein.

Sato K, Okajima F.

World J Biol Chem. 2010 Nov 26;1(11):327-37. doi: 10.4331/wjbc.v1.i11.327.

17.
18.

Blood sphingolipidomics in healthy humans: impact of sample collection methodology.

Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B, Klein RL, Hannun YA, Bielawski J, Bielawska A.

J Lipid Res. 2010 Oct;51(10):3074-87. doi: 10.1194/jlr.D008532. Epub 2010 Jul 21.

19.

HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate.

Lee MH, Hammad SM, Semler AJ, Luttrell LM, Lopes-Virella MF, Klein RL.

J Lipid Res. 2010 Sep;51(9):2619-28. doi: 10.1194/jlr.M003988. Epub 2010 Jun 3.

20.

Enhanced hepatic apoA-I secretion and peripheral efflux of cholesterol and phospholipid in CD36 null mice.

Yue P, Chen Z, Nassir F, Bernal-Mizrachi C, Finck B, Azhar S, Abumrad NA.

PLoS One. 2010 Mar 26;5(3):e9906. doi: 10.1371/journal.pone.0009906.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk